Low-density lipoprotein cholesterol lowering in the prevention of CHD: How low should we go?

Current Treatment Options in Cardiovascular Medicine

Volumn 8, Issue 4, 2006, Pages 289-297

  Isley, William L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYTOCHROME P450 3A4; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; EXERCISE; FLUSHING; GLUCOSE INTOLERANCE; GOUT; HEALTH CARE AVAILABILITY; HEART INFARCTION; HEMATURIA; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIVER DYSFUNCTION; LIVER TOXICITY; MEDICAL EDUCATION; MORTALITY; PRIMARY PREVENTION; PROPHYLAXIS; REVIEW; RISK FACTOR; SECONDARY PREVENTION;

EID: 33746150058     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-006-0050-6     Document Type: Review

References (34)

1. Thom T, Haase N, Rosamond W, et al.: Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113:e85-e151.
2. de Lorgeril M, Salen P, Monjaud I, Delaye J: The diet heart hypothesis in secondary prevention of coronary heart disease. Eur Heart J 1997, 18:14-18.
3. Howard BV, Van Horn L, Hsia J, et al.: Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006, 295:655-666.
4. Oliver MF: Statins prevent coronary heart disease. Lancet 1995, 346:1378-1379.
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) [no authors listed]. Lancet 1994, 344:1383-1389.
6. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
7. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
8. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
9. Grundy SM, Cleeman JI, Merz NB, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
10. Topol EJ: Intensive status therapy - a sea change in cardiovascular prevention. N Engl J Med 2004, 350:1562-1564.
11. O'Keefe JH Jr, Cordain L, Harris WH, et al.: Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004, 43:2142-2146.
12. Sever PS, Dahlöf B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003, 361:1149-1158.
13. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre rendomised placebo-controlled trial. Lancet 2004, 364:685-695.
14. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group [no authors listed]. N Engl J Med 1998, 339:1349-1357.
15. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Heart Protection Study Collaborative Group [no authors listed]. Lancet 2002, 360:7-22.
16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998-3007.
17. Shepherd J, Blauw GJ, Murphy MB, et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002, 360:1623-1630.
18. LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
19. Pedersen TR, Faergeman O, Kastelein JJP, et al.: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. the IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445.
20. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
21. de Lemos JA, Blazing MA, Wiviott SD, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z Trial. JAMA 2004, 292:1307-1316.
22. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease [LIPID] Study Group [no authors listed]. N Engl J Med 1998, 339:1349-1357.
23. Montori VM, Busse JW, Permanyer-Miralda G, et al.: How should clinicians interpret results reflecting the effect of an intervention on composite endpoints: should I dump this lump? ACP J Club 2005, 143:A8-A9.
24. Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
25. Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080.
26. Nissen SE, Nicholls SJ, Sipahi I, et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:E1-E10.
27. Blumenthal RS, Kapur NK: Can a potent statin actually regress coronary atherosclerosis? JAMA 2006, 295:E1-E2.
28. Schmermund A, Achenbach S, Budde T, et al.: Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months. Circulation 2006, 113:427-437.
29. Stone PH, Lloyd-Jones DM, Kinlay S, et al.: Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease. Circulation 2005, 111:1747-1755.
30. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410-418.
31. Katan MB, Grundy SM, Jones P, et al.: Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003, 78:965-978.
32. Serruys PW, de Feyter P, Macaya C, et al.: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 287:3215-3222.
33. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease [no authors listed]. JAMA 1984, 251:351-364.
34. Canner PL, Berge KG, Wenger NK, et al.: Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.